Cited by 1,336Renal cell carcinoma treatmentCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

Open access

The Cancer Genome Atlas Research Network·2016·New England Journal of Medicine

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1505917

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citation
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citation
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635

Flagged first, then by citations

Show all 42 references

1 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Delahunt B, 1997, Mod Pathol, 10, 537
Schmidt LS, 1998, Cancer Res, 58, 1719

Sorted by citations

Items 101–200 of 1,000

A chemoproteomic portrait of the oncometabolite fumarate
Kulkarni, R. A., Bak, D. W., Wei, D., Bergholtz, S. E., Briney, C. A., Shrimp, J. H., Alpsoy, A., Thorpe, A. L., Bavari, A. E., Crooks, D. R., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0217-y · Cited by 122
GPNMB expression identifies TSC1 /2/ mTOR ‐associated and MiT family translocation‐driven renal neoplasms
Salles, D. C., Asrani, K. V., Woo, J., Vidotto, T., Liu, H. B., Vidal, I., Matoso, A., Netto, G. J., Argani, P., & Lotan, T. L. (2022) · The Journal of Pathology · doi:10.1002/path.5875 · Cited by 122
YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells
White, S. M., Avantaggiati, M. L., Nemazanyy, I., Poto, C. D., Yang, Y., Pende, M., Gibney, G. T., Ressom, H. W., Field, J., Atkins, M. B., et al. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.014 · Cited by 121
RBM10-TFE3 Renal Cell Carcinoma
Argani, P., Zhang, L., Reuter, V. E., Tickoo, S. K., & Antonescu, C. R. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000835 · Cited by 117
Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling
Pal, S. K., Ali, S. M., Yakirevich, E., Geynisman, D. M., Karam, J. A., Elvin, J. A., Frampton, G. M., Huang, X., Lin, D. I., Rosenzweig, M. R., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.033 · Cited by 119
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Schöffski, P., Woźniak, A., Escudier, B. J., Rutkowski, P. L., Anthoney, A., Bauer, S., Šufliarský, J., van Herpen, C., Lindner, L. H., Grünwald, V., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.014 · Cited by 117
CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence
Zhao, Y., Pan, Z., Namburi, S., Pattison, A., Posner, A., Balachander, S., Paisie, C. A., Reddi, H. V., Rueter, J., Gill, A. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103030 · Cited by 120
New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
Rassy, E., Parent, P., Lefort, F., Boussios, S., Baciarello, G., & Pavlidis, N. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102882 · Cited by 117
Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers
Su, C., Lv, Y., Lu, W., Yu, Z., Ye, Y., Guo, B., Liu, D., Yan, H., Li, T., Zhang, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719564 · Cited by 123
Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism
Valcárcel-Jiménez, L., & Frezza, C. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02412-w · Cited by 117
A distinctive, low‐grade oncocytic fumarate hydratase‐deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase‐deficient renal cell carcinoma
Smith, S. C., Sirohi, D., Ohe, C., McHugh, J. B., Hornick, J. L., Kalariya, J. J., Karia, S., Snape, K. M. G., Hodgson, S. V., Cani, A. K., et al. (2017) · Histopathology · doi:10.1111/his.13183 · Cited by 114
Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers
Cheng, J., Wei, D., Ji, Y., Chen, L., Yang, L., Li, G., Wu, L., Hou, T., Xie, L., Ding, G., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0548-z · Cited by 114
Interplay Among Metabolism, Epigenetic Modifications, and Gene Expression in Cancer
Huo, M., Zhang, J., Huang, W., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793428 · Cited by 117
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma
Li, F., Aljahdali, I. A. M., Zhang, R., Nastiuk, K. L., Krolewski, J. J., & Ling, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02026-1 · Cited by 114
WHO 2022 landscape of papillary and chromophobe renal cell carcinoma
Lobo, J., Ohashi, R., Amin, M. B., Berney, D. M., Compérat, É., Cree, I. A., Gill, A. J., Hartmann, A., Menon, S. G., Netto, G. J., et al. (2022) · Histopathology · doi:10.1111/his.14700 · Cited by 113
TCGA Expedition: A Data Acquisition and Management System for TCGA Data
Chandran, U. R., Medvedeva, O. P., Barmada, M. M., Blood, P. D., Chakka, A. B., Luthra, S., Ferreira, A. M., Wong, K. F., Lee, A. V., Zhang, Z., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165395 · Cited by 114
Acute kidney injury promotes development of papillary renal cell adenoma and carcinoma from renal progenitor cells
Peired, A. J., Antonelli, G., Angelotti, M. L., Allinovi, M., Guzzi, F., Sisti, A., Semeraro, R., Conte, C., Mazzinghi, B., Nardi, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw6003 · Cited by 112
Patient‐derived renal cell carcinoma organoids for personalized cancer therapy
Li, Z., Xu, H., Yu, L., Wang, J., Meng, Q., Mei, H., Cai, Z., Chen, W., & Huang, W. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.970 · Cited by 120
Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays
Skala, S. L., Xiao, H., Udager, A. M., Dhanasekaran, S. M., Shukla, S. K., Zhang, Y., Landau, C., Shao, L., Roulston, D., Wang, L., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.99 · Cited by 112
Renal cell carcinoma: the search for a reliable biomarker
Farber, N. J., Kim, C. J., Modi, P. K., Hon, J. D., Sadimin, E. T., & Singer, E. A. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.05.19 · Cited by 114
Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers
Williamson, S. R., Gill, A. J., Argani, P., Chen, Y., Egevad, L., Kristiansen, G., Grignon, D. J., & Hes, O. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001476 · Cited by 112
Cell-Type-Specific Gene Programs of the Normal Human Nephron Define Kidney Cancer Subtypes
Lindgren, D., Eriksson, P., Krawczyk, K. M., Nilsson, H., Hansson, J., Veerla, S., Sjölund, J., Höglund, M., Johansson, M., & Axelson, H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.043 · Cited by 111
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Labbé, D. P., Sweeney, C. J., Brown, M. A., Galbo, P. M., Rosario, S. R., Wadosky, K. M., Ku, S., Sjöström, M., Alshalalfa, M., Erho, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0413 · Cited by 111
Heterogeneity in renal cell carcinoma
Beksac, A. T., Paulucci, D. J., Blum, K. A., Yadav, S. S., Sfakianos, J. P., & Badani, K. K. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.05.006 · Cited by 111
Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis
Saleeb, R., Brimo, F., Farag, M. S., Rompré‐Brodeur, A., Rotondo, F., Beharry, V., Wala, S. J., Plant, P. J., Downes, M. R., Pace, K. T., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000962 · Cited by 106
Classification of renal cell tumors – current concepts and use of ancillary tests: recommendations of the Brazilian Society of Pathology
Athanazio, D. A., Amorim, L. S., da Cunha, I. W., Leite, K. R. M., da Paz, A. R., Gomes, R. D. P. X., Tavora, F. R. F., Faraj, S. F., Cavalcanti, M. S., & Bezerra, S. M. (2021) · Surgical and Experimental Pathology · doi:10.1186/s42047-020-00084-x · Cited by 104
Early loss of mitochondrial complex I and rewiring of glutathione metabolism in renal oncocytoma
Gopal, R. K., Calvo, S. E., Shih, A. R., Chaves, F. L., McGuone, D., Mick, E., Pierce, K. A., Li, Y., Garofalo, A., Allen, E. M. V., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711888115 · Cited by 102
Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
Sun, G., Zhang, X., Liang, J., Pan, X., Zhu, S., Liu, Z., Armstrong, C. M., Chen, J., Lin, W., Liao, B., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3788 · Cited by 102
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies
Xiao, Y., & Meierhofer, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153672 · Cited by 104
TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management
Gupta, S., Johnson, S. H., Vasmatzis, G., Porath, B., Rustin, J. G., Rao, P., Costello, B. A., Leibovich, B. C., Thompson, R. H., Cheville, J. C., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.24 · Cited by 101
PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
Bădoiu, S. C., Greabu, M., Miricescu, D., Stănescu-Spînu, I.-I., Ilinca, R., Bălan, D. G., Balcangiu‐Stroescu, A.-E., Mihai, D. A., Văcăroiu, I. A., Ștefani, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098391 · Cited by 101
Immune checkpoint inhibitors in renal cell carcinoma
Ross, K., & Jones, R. J. (2017) · Clinical Science · doi:10.1042/cs20160894 · Cited by 100
Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia
Yang, M., Vesterlund, M., Siavelis, I., Moura‐Castro, L. H., Castor, A., Fioretos, T., Jafari, R., Lilljebjörn, H., Odom, D. T., Olsson, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09469-3 · Cited by 101
Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma
Zhang, C., Zheng, Y., Li, X., Hu, X., Qi, F., & Luo, J. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.113 · Cited by 95
Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling
Calcagnì, A., Kors, L., Verschuren, E. H. J., Cegli, R. D., Zampelli, N., Nusco, E., Confalonieri, S., Bertalot, G., Pece, S., Settembre, C., et al. (2016) · eLife · doi:10.7554/elife.17047 · Cited by 95
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape
Wang, Z., Kim, T. B., Peng, B., Karam, J. A., Creighton, C. J., Joon, A. Y., Kawakami, F., Trevisan, P., Jonasch, E. W., Chow, C.-W. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1057 · Cited by 95
Challenges and opportunities in the proteomic characterization of clear cell renal cell carcinoma (ccRCC): A critical step towards the personalized care of renal cancers
Li, Q. K., Pavlovich, C. P., Zhang, H., Kinsinger, C. R., & Chan, D. W. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.004 · Cited by 98
Recent advances in understanding the complexities of metastasis
Chitty, J. L., Filipe, E. C., Lucas, M. C., Herrmann, D., Cox, T. R., & Timpson, P. (2018) · F1000Research · doi:10.12688/f1000research.15064.2 · Cited by 97
Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals
Forde, C., Lim, D., Alwan, Y., Burghel, G. J., Butland, L., Cleaver, R., Dixit, A., Evans, D. G., Hanson, H., Lalloo, F. I., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.11.002 · Cited by 95
Epigenetic modifiers: activities in renal cell carcinoma
de Cubas, A. A., & Rathmell, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0052-7 · Cited by 97
Papillary renal cell carcinoma: Review
Mendhiratta, N., Muraki, P., Sisk, A. E. J., & Shuch, B. M. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.04.013 · Cited by 92
Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney
Mehra, R., Vats, P., Cieslik, M. P., Cao, X., Su, F., Shukla, S. K., Udager, A. M., Wang, R., Pan, J., Kasaian, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0267 · Cited by 91
Current updates and future perspectives on the management of renal cell carcinoma
Singh, D. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118632 · Cited by 91
Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers
Shu, J., Silva, B. V. R. E., Gao, T. X., Xu, Z. Q., & Cui, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-13470-5 · Cited by 98
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non–Clear Cell Renal Cell Carcinoma
Voss, M. H., Molina, A. M., Chen, Y., Woo, K. M., Chaim, J. L., Coskey, D. T., Redzematovic, A., Wang, P., Lee, W., Selçuklu, S. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9084 · Cited by 88
High throughput estimation of functional cell activities reveals disease mechanisms and predicts relevant clinical outcomes
Hidalgo, M. R., Çubuk, C., Amadoz, A., Salavert, F., Carbonell‐Caballero, J., & Dopazo, J. (2016) · Oncotarget · doi:10.18632/oncotarget.14107 · Cited by 91
Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma
Pal, S. K., Bergerot, P. G., Dizman, N., Bergerot, C. D., Adashek, J. J., Madison, R. W., Chung, J., Ali, S. M., Jones, J. O., & Salgia, R. (2018) · European Urology · doi:10.1016/j.eururo.2018.03.032 · Cited by 88
Mutations in renal cell carcinoma
D’Avella, C. A., Abbosh, P. H., Pal, S. K., & Geynisman, D. M. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.027 · Cited by 89
Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas
Remacha, L., Pirman, D. A., Mahoney, C. E., Coloma, J., Calsina, B., Currás-Freixes, M., Letón, R., Torres‐Pérez, R., Richter, S., Pita, G., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.017 · Cited by 88
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Gleeson, J. P., Nikolovski, I., DiNatale, R. G., Zucker, M. R., Knežević, A., Patil, S., Ged, Y. M. A., Kotecha, R. R., Shapnik, N., Murray, S. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4367 · Cited by 88
Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas
Classe, M., Malouf, G. G., Su, X., Yao, H., Thompson, E. J., Doss, D. J., Grégoire, V., Nobin, J. L., Fantoni, J. C., Sudour‐Bonnange, H., et al. (2017) · Histopathology · doi:10.1111/his.13167 · Cited by 88
Transferrin receptor 1 upregulation in primary tumor and downregulation in benign kidney is associated with progression and mortality in renal cell carcinoma patients
Greene, C. J., Attwood, K., Sharma, N. J., Gross, K. W., Smith, G. J., Xu, B., & Kauffman, E. C. (2017) · Oncotarget · doi:10.18632/oncotarget.22323 · Cited by 87
The potential of organoids in urological cancer research
Wang, S., Gao, D., & Chen, Y. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.65 · Cited by 87
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost MethylationPreprint
Fahey, C. C., & Davis, I. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026468 · Cited by 92
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
Grampp, S., Platt, J. L., Lauer, V., Salama, R. A., Kranz, F., Neumann, V. K., Wach, S., Stöhr, C., Hartmann, A., Eckardt, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13183 · Cited by 88
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 88
Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma
Dinh, T. A., Vitucci, E. C. M., Wauthier, E., Graham, R. P., Pitman, W. A., Oikawa, T., Chen, M., Silva, G. O., Greene, K. G., Torbenson, M. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44653 · Cited by 89
Long-read transcriptome sequencing reveals abundant promoter diversity in distinct molecular subtypes of gastric cancer
Huang, K. K., Huang, J., Wu, J., Lee, M., Tay, S. T., Kumar, V., Ramnarayanan, K., Padmanabhan, N., Xu, C., Tan, A. L. K., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02261-x · Cited by 88
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research
Ooi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.016 · Cited by 85
Whole genome DNA sequencing provides an atlas of somatic mutagenesis in healthy human cells and identifies a tumor-prone cell type
Franco, I., Helgadottir, H. T., Moggio, A., Larsson, M., Vrtačnik, P., Johansson, A., Norgren, N., Lundin, P., Mas-Ponte, D., Nordström, J., et al. (2019) · Genome biology · doi:10.1186/s13059-019-1892-z · Cited by 83
Prognostic Factors for Renal Cell Carcinoma Subtypes Diagnosed According to the 2016 WHO Renal Tumor Classification: a Study Involving 928 Patients
Kuthi, L., Jenei, A., Hajdu, A., Németh, I., Varga, Z., Bajory, Z., Pajor, L., & Iványi, B. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0179-x · Cited by 83
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation
Bamias, A., Escudier, B. J., Sternberg, C. N., Zagouri, F., Dellis, A., Djavan, B., Tzannis, K., Kontovinis, L., STRAVODIMOS, K. G., Papatsoris, A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0435 · Cited by 82
Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma
Marostica, E., Barber, R., Denize, T., Kohane, I. S., Signoretti, S., Golden, J. A., & Yu, K. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4119 · Cited by 83
TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease
Baba, M., Furuya, M., Motoshima, T., Lang, M., Funasaki, S., Ma, W., Sun, H., Hasumi, H., Huang, Y. K., Kato, I., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1235 · Cited by 82
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 83
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection
Sinha, R., Winer, A., Chevinsky, M. S., Jakubowski, C. D., Chen, Y., Dong, Y., Tickoo, S. K., Reuter, V. E., Russo, P., Coleman, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15165 · Cited by 86
Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression
Cao, S., Wang, J. R., Ji, S., Peng, Y., Dai, Y., Guo, S., Montierth, M. D., Shen, J. P., Zhao, X. H., Chen, J., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01342-x · Cited by 81
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)
Suárez, C., Larkin, J., Patel, P. M., Valderrama, B. P., Rodríguez‐Vida, A., Glen, H., Thistlethwaite, F. C., Ralph, C., Srinivasan, G., Méndez, M. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01414 · Cited by 80
Computational analysis of pathological images enables a better diagnosis of TFE3 Xp11.2 translocation renal cell carcinoma
Cheng, J., Han, Z., Mehra, R., Shao, W., Cheng, M., Feng, Q., Ni, D., Huang, K., Liang Cheng, C., & Zhang, J. (2020) · Nature Communications · doi:10.1038/s41467-020-15671-5 · Cited by 80
Recurrent KRAS mutations in papillary renal neoplasm with reverse polarity
Al‐Obaidy, K. I., Eble, J. N., Nassiri, M., Liang Cheng, C., Eldomery, M. K., Williamson, S. R., Sakr, W., Gupta, N., Hassan, O., Idrees, M. T., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0362-1 · Cited by 79
Choosing The Right Animal Model for Renal Cancer Research
Sobczuk, P., Brodziak, A., Khan, M. I., Chhabra, S., Fiedorowicz, M., Wełniak-Kamińska, M., Synoradzki, K. J., Bartnik, E., Cudnoch‐Jędrzejewska, A., & Czarnecka, A. M. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100745 · Cited by 81
Predicting master transcription factors from pan-cancer expression data
Reddy, J., Fonseca, M. A., Corona, R. I., Nameki, R. A., Dezem, F. S., Klein, I. A., Chang, H. S. Y., Chaves‐Moreira, D., Afeyan, L. K., Malta, T. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6123 · Cited by 82
Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene
Williamson, S. R., Grignon, D. J., Liang Cheng, C., Favazza, L. A., Gondim, D. D., Carskadon, S. L., Gupta, N., Chitale, D. A., Sundaram, S. K., & Palanisamy, N. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000776 · Cited by 77
Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers
Signoretti, S., Flaifel, A., Chen, Y., & Reuter, V. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2259 · Cited by 76
Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma
Bihr, S., Ohashi, R., Moore, A. L., Rüschoff, J. H., Beisel, C., Hermanns, T., Mischo, A., Corrò, C., Beyer, J., Beerenwinkel, N., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2018.12.006 · Cited by 82
Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma
Seles, M., Hutterer, G. C., Kiesslich, T., Pummer, K., Berindan‐Neagoe, I., Perakis, S. O., Schwarzenbacher, D., Stotz, M., Gerger, A., & Pichler, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040573 · Cited by 75
Node-aligned Graph Convolutional Network for Whole-slide Image Representation and Classification
Guan, Y., Zhang, J., Tian, K., Yang, S., Dong, P., Xiang, J., Yang, W., Huang, J., Zhang, Y., & Han, X. (2022) · IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings - IEEE Computer Society Conference on Computer Vision and Pattern Recognition/Proceedings · doi:10.1109/cvpr52688.2022.01825 · Cited by 79
Translocation carcinomas of the kidney
Argani, P. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23007 · Cited by 73
Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity—a comparative study with papillary renal cell carcinoma
Kim, S. S., Cho, Y. M., Kim, G. H., Kee, K.-H., Kim, H., Kim, K. M., Kim, J., & Choi, C. (2020) · Modern Pathology · doi:10.1038/s41379-019-0420-8 · Cited by 73
The Role of DNA Methylation in Renal Cell Carcinoma
Lasseigne, B. N., & Brooks, J. D. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0337-9 · Cited by 75
A semi-supervised multi-task learning framework for cancer classification with weak annotation in whole-slide images
Gao, Z., Hong, B., Li, Y., Zhang, X., Wu, J., Wang, C., Zhang, X., Gong, T., Zheng, Y., Meng, D., et al. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102652 · Cited by 73
Molecular insights into genome-wide association studies of chronic kidney disease-defining traits
Xu, X., Eales, J., Akbarov, A., Guo, H., Becker, L. K., Talavera, D., Ashraf, F., Nawaz, J., Pramanik, S., Bowes, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07260-4 · Cited by 73
Construction of immune‐related risk signature for renal papillary cell carcinoma
Wang, Z., Song, Q., Yang, Z., Chen, J., Shang, J., & Ju, W. (2018) · Cancer Medicine · doi:10.1002/cam4.1905 · Cited by 71
JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management
Gupta, S., Cheville, J. C., Jungbluth, A. A., Zhang, Y., Zhang, L., Chen, Y., Tickoo, S. K., Fine, S. W., Gopalan, A., Al‐Ahmadie, H. A., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0269-x · Cited by 73
Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention
Ball, M. W., An, J. Y., Gomella, P. T., Gautam, R., Ricketts, C. J., Vocke, C. D., Schmidt, L. S., Merino, M. J., Srinivasan, R., Malayeri, A. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02263 · Cited by 71
Precision medicine from the renal cancer genome
Riazalhosseini, Y., & Lathrop, M. G. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.133 · Cited by 69
Lung Cancer Heterogeneity and New Strategies for Drug Therapy
Wang, D. C., Wang, W. Y., Zhu, B., & Wang, X. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104523 · Cited by 69
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma
Lasseter, K. D., Nassar, A. H., Hamieh, L., Berchuck, J. E., Nuzzo, P. V., Korthauer, K. D., Shinagare, A. B., Ogórek, B., McKay, R. R., Thorner, A. R., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0801-x · Cited by 72
Recognition of the polycistronic nature of human genes is critical to understanding the genotype-phenotype relationshipPreprint
Brunet, M. A., Levesque, S. A., Hunting, D. J., Cohen, A. A., & Roucou, X. (2018) · Genome Research · doi:10.1101/gr.230938.117 · Cited by 75
The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Wu, W., & Papagiannakopoulos, T. Y. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055627 · Cited by 70
Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC)
Argani, P., Reuter, V. E., Eble, J. N., Vlatkovic, L., Yaskiv, O., Swanson, D. M., Dickson, B. C., Antonescu, C. R., Matoso, A., Gagan, J., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001467 · Cited by 68
Flavonoids targeting NRF2 in neurodegenerative disorders
Khan, H. Z., Tundis, R., Ullah, H., Aschner, M., Belwal, T., Mirzaei, H., & Akkol, E. K. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111817 · Cited by 68
Cancer biology deciphered by single-cell transcriptomic sequencing
Li, Y., Jin, J., & Bai, F. (2021) · Protein & Cell · doi:10.1007/s13238-021-00868-1 · Cited by 67
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
Smith, K. E. R., & Bilen, M. A. (2019) · Kidney Cancer · doi:10.3233/kca-190058 · Cited by 68
Ultrahigh thermal conductivity confirmed in boron arsenide
Dames, C. (2018) · Science · doi:10.1126/science.aau4793 · Cited by 68
Morphologic, Molecular, and Taxonomic Evolution of Renal Cell Carcinoma: A Conceptual Perspective With Emphasis on Updates to the 2016 World Health Organization Classification
Udager, A. M., & Mehra, R. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0218-ra · Cited by 66
Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
Campbell, M. T., Bilen, M. A., Shah, A. Y., Lemke, E., Jonasch, E. W., Venkatesan, A. M., Altinmakas, E., Duran, C., Msaouel, P., & Tannir, N. M. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.014 · Cited by 66
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
Gan, H. K., Millward, M., Ye, H., Qi, C., Sai, Y., Su, W., Wang, J., Zhang, L., Frigault, M. M., Morgan, S. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1189 · Cited by 66
The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age
Huang, J. J., & Hsieh, J. J.-D. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.12.004 · Cited by 70

Authors: The Cancer Genome Atlas Research Network
Affiliations: National Institutes of Health (US)
Corresponding author: The Cancer Genome Atlas Research Network
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-01-14
Volume: 374
Issue: 2
Pages: 135-145
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1505917
PMC: PMC4775252
OpenAlex: W2111867681
Cited by: 1,336
References: 42
Citations by year: 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
FWCI: 92.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (UL1TR000005)
National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
MeSH terms: Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks